[C:1]([O:5][C:6](=[O:25])[NH:7][CH:8]1[CH:18]2[CH2:19][CH2:20][CH:9]1[CH2:10][C:11]1[CH:12]=[C:13]([CH2:21][CH2:22][CH:23]=O)[CH:14]=[CH:15][C:16]=1[CH2:17]2)([CH3:4])([CH3:3])[CH3:2].Cl.[F:27][C:28]([F:36])([F:35])[CH:29]1[CH2:34][CH2:33][NH:32][CH2:31][CH2:30]1.C([BH3-])#N.[Na+]>CO>[C:1]([O:5][C:6](=[O:25])[NH:7][CH:8]1[CH:18]2[CH2:19][CH2:20][CH:9]1[CH2:10][C:11]1[CH:12]=[C:13]([CH2:21][CH2:22][CH2:23][N:32]3[CH2:33][CH2:34][CH:29]([C:28]([F:36])([F:35])[F:27])[CH2:30][CH2:31]3)[CH:14]=[CH:15][C:16]=1[CH2:17]2)([CH3:4])([CH3:3])[CH3:2]The product from Step 2 (140 mg, 0.408 mmol), 4-trifluoromethylpiperidine hydrochloride (78 mg, 0.408 mmol) and sodium cyanoborohydride (77 mg, 1.22 mmol) in methanol (15 ml) were stirred at room temperature for 18 hours. The mixture was quenched with water and then with sodium bicarbonate solution (sat). The product was extracted with DCM and the organic phase was dried and concentrated. The crude product was purified by column chromatography on silica gel eluting with 40:1 DCM-2M NH3 in MeOH to give a colourless oil. The product was re-purified by column chromatography on silica gel eluting with 7:1 isohexane-ethyl acetate to give a colourless oil 87 mg (44%). 1H NMR (CDCl3, 400 MHz) δ 6.99 (1H, d, J=8.0 Hz), 6.89 (2H, m), 4.98 (1H, m), 4.02 (1H, m), 2.95–3.02 (4H, m), 2.45–2.62 (6H, m), 2.35 (2H, m), 1.58–2.04 (11H, m), 1.47 (9H, m), 1.19 (2H, m). m/z 481 (M+H+).